DFX Intelligence
Venture Capital Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Venture Capital Intelligence at $199 a month for every name. Every figure, date and source on this page is public either way.
Firms / A•••• M••••••••• L••
A•••• M••••••••• L••
••• Locked
corporate parent: self-described
Importance
23
moderate
Active deployment
55
elevated
Emerging
0
low
Completeness
75
high
Freshness
98
high
Research priority
17
moderate
Identity and regulatory footprint
- Headquarters
- Alpharetta, GAadviserinfo.sec.gov
- Office address
- ••• Lockedadviserinfo.sec.gov
- Business phone
- ••• Lockedadviserinfo.sec.gov
- Website
- a••••.com
- SEC adviser type
- registered investment adviseradviserinfo.sec.gov
- SEC exemption claimed
- unknown
- Latest Form ADV
- Mar 31, 2026
- Private funds reported
- 7 (1 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $918Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Regulatory AUM
- $918Mthe adviser's RAUM, a regulatory measure, never a fund size
- Employees
- 16
- business email
- contact@avego.comavego.compublished by the subject
- business phone
- 646-844-0030adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
16 observed deals
Stated (the firm’s website)
- Sectors
- fintech, healthcare, biotech, medtech, industrial, media
- Stages
- series a, series b, growth, multi stage
- Geography
- atlanta, boston, global, globally, heartland, new york, philadelphia, uk
- Check size
- not stated; DFX does not estimate checks from round sizes
- Self-described
- corporate venture
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
unknown 69%Biotechnology 19%Other 6%Other Health Care 6%
lead rate n/afollow-on rate n/anew logos, 12 months 16
Funds and vehicles
2 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| A•••• B••••••••• C•••••• F••• I•• L••• | Fund | 2026 form d first sale | Fundraising | unknown | unknown | $60.0M | Apr 6, 2026 |
| A•••• B••••••••• C••••••• L••• | Fund | 2021 form d first sale | Mature | $91.7M Oct 25, 2024 | 19 | $68.7M | Mar 7, 2025 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
4 current, 1 departed
B••••• N•• V•••••••••
Managing partnerPartner, Managing Member · since Jun 1, 2020
J•••• M•••••• F••••••
PartnerPartner, Member · since Jun 1, 2020
T••••• R•••••• V•••••••••
PartnerPartner, Member · since Jun 1, 2020
A••••• A•••• R•••••
Platform and operationsChief Compliance Officer And Chief Financial Officer · since Jul 1, 2023
1 departed (kept with end dates)
- J•••• Z••••• · Chief Compliance Officer, Chief Financial Officer · Mar 1, 2021 to Jul 21, 2023 Inference
Investments on record
16 edges, 16 companies, 0 partner-attributed
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
8 relationships from shared deals, counted for the whole firm
Mission Biocapital 2 shared · recurringFemhealth Ventures Management LLC 1 shared · one timeOmega Fund Management, LLC 1 shared · one timeVivo Capital, LLC 1 shared · one timePascal Capital, L.L.C. 1 shared · one timeCatalio Capital Management, LP 1 shared · one timeFuture Planet Capital Limited 1 shared · one timeCSC Upshot Ventures Management, LLC 1 shared · one time
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
6 dated events
- Sep 15, 2026A•••• M••••••••• L••: PE_WITH_VENTURE_ACTIVITY -> CORPORATE_VENTURE (corporate parent: self-described)Classification changedClassificationInferenceno URL
- Jul 21, 2023J•••• Robert Z••••• (Chief Compliance Officer, Chief Financial Officer) no longer on Schedule A of A•••• M••••••••• L••
- Jul 1, 2023A••••• A•••• R••••• joined Schedule A of A•••• M••••••••• L•• as Chief Compliance Officer And Chief Financial Officer
- Mar 31, 2022A•••• B••••••••• C••••••• L••• first reported on Form ADV by A•••• M••••••••• L•• (Private Equity Fund), GAV $23,181,530Fund first reported on Form ADVFundsFactA•••• B••••••••• C••••••• L•••SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 1, 2021J•••• Z••••• joined Schedule A of A•••• H•••••care Capital as Chief Compliance Officer
- Dec 16, 2020A•••• M••••••••• L•• first filed Form ADV (IA)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 15, 2026Corporate venture (probable, 80%, cls-1)corporate parent: self-described
- Sep 12, 2026Private equity with venture activity (probable, 75%, cls-1)registered adviser; venture funds are 12% of 7 private funds
- Sep 12, 2026Private equity with venture activity (probable, 75%, cls-1)registered adviser; venture funds are 12% of 6 private funds
Evidence
54 observations from 3 sources